Vericel Secures $197 Million BARDA Contract for NexoBrid Burn Treatment

Vericel Corporation has announced a new agreement with the Biomedical Advanced Research and Development Authority (BARDA) for the procurement and advanced development of NexoBrid, a burn treatment product. The contract is valued at up to $197 million, encompassing both immediate procurement and potential future funding for additional development activities.

According to details provided by Vericel, the agreement includes an initial commitment from BARDA to purchase NexoBrid for emergency stockpiling purposes. The contract also outlines provisions for further funding aimed at supporting continued research and development of the product. NexoBrid is designed to remove non-viable tissue in patients with severe thermal burns, offering an alternative to surgical debridement. This collaboration builds on previous partnerships between Vericel and BARDA, which have focused on advancing treatments for burn care in mass casualty scenarios.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 2, 2026

Author

GOAI